Geographic Differences in Dupilumab Treatment Outcomes for Atopic Dermatitis: A Systematic Review and Meta-Regression...

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Dupilumab, a monoclonal antibody targeting IL-4/IL-13, is effective for atopic dermatitis.
• Real-world dupilumab efficacy and geographic variations are not well understood.

Purpose of the Study:

• To assess geographic influences on dupilumab efficacy (EASI reduction).
• To evaluate geographic variations in adverse events (AEs) associated with dupilumab treatment.

Main Methods:

• Systematic review and meta-regression of 28 studies.
• Analysis adjusted for geographic region, baseline EASI, and female participant proportion.
• Risk of bias assessed using ROBINS-1 tool.

Main Results:

• Southern Europeans achieved 15.33% greater EASI reduction than East Asians and 10.2% greater than Northern/Central Europeans.
• Adverse events were most frequent in Northern/Central Europeans.
• Geographic variations in AE types were observed.

Conclusions:

• Geographic factors significantly influence dupilumab's clinical efficacy and safety in atopic dermatitis.
• Underlying mechanisms for observed geographic variations require further investigation.